Evidence brief
Bisphosphonate Treatment for Osteogenesis Imperfecta
Cyclic IV pamidronate increases BMD in OI
Reduces fracture rate significantly
Improves mobility and reduces pain
Started treatment paradigm for severe OI
Long-term effects being monitored
Bisphosphonate therapy transformed management of moderate-severe OI, reducing fracture rates and improving quality of life.
Know Sillence classification (I-IV). Treatment: bisphosphonates (pamidronate IV, zoledronic acid) for moderate-severe types. Surgical: rodding (Rush, Fassier-Duval telescoping). Multidisciplinary care essential. Discuss concerns about long-term bisphosphonate use in children.
Level II
Lesser quality RCT or prospective comparative study